AIMD

Ainos, Inc. (AIMD) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Ainos, Inc. is a dual-platform company developing AI-enabled olfactory sensing technologies ("AI Nose" or "SmellTech") and immune therapeutics ("VELDONA"). The company operates as a single segment and is classified as a smaller reporting company. As of June 30, 2026, the company had 7,384,073 shares of common stock outstanding.

Key Financial Metrics

Note: Total Current Debt includes $11,000,000 in convertible notes and $2,812,940 in a loan payable.

Material Changes vs. Prior Period

• Revenue Collapse: Revenue dropped 97% in Q2 2026 ($152) compared to Q2 2025 ($4,663). For the six months ended June 30, 2026, revenue was $313 versus $110,870 in the prior year period. Management attributes this to a strategic shift away from VELDONA pet supplement sales and healthcare-adjacent AI Nose applications toward industrial deployments which are in earlier commercialization stages.
• Expense Management: Total operating expenses increased 17% in Q2 2026 ($4.40M) compared to Q2 2025 ($3.75M), driven by a 39% increase in SG&A expenses due to higher share-based compensation and professional fees. However, for the six-month period, total operating expenses decreased 5% ($6.68M vs $7.00M).
• Debt Structure: The company incurred significant new debt in the first half of 2026. A $2.81M loan from ASE Test, Inc. was drawn in March 2026. Additionally, $11M in convertible notes were reclassified from non-current to current liabilities as they matured or were amended.
• Net Loss: Net loss increased 12% in Q2 2026 compared to the prior year quarter but decreased 4% for the six-month period ($7.05M vs $7.37M).

Outlook, Risks, and Management Commentary

• Going Concern Warning: The filing explicitly states that "substantial doubt exists about the Company's ability to continue as a going concern" for at least one year from the issuance date. The company has an accumulated deficit of $74.6M and expects to incur additional losses.
• Liquidity Strategy: Management plans to fund operations through existing cash ($1.42M), the At-the-Market (ATM) offering facility, and potential debt financing. In H1 2026, the company raised $601,600 via the ATM facility.
• Strategic Focus: Priorities for 2026 include advancing AI Nose commercialization in semiconductor manufacturing, robotics, and industrial infrastructure. The company is pursuing "SmellTech-As-A-Service" models. VELDONA development is being managed in a capital-efficient manner with a focus on out-licensing.
• Risks: Key risks include the inability to secure additional financing, supply chain constraints for AI Nose components, and foreign currency fluctuations (significant operations in Taiwan). The company also faces potential patent litigation risks common in its industry.
• Subsequent Events: On July 10, 2026, the company extended the maturity date of a portion ($1.94M) of its ASE Test loan to July 31, 2027.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance of $1.42M is sufficient to cover the ~$2.4M operating cash burn rate observed in H1 2026 without immediate new financing.
• Debt Maturity: Confirm the repayment terms and conversion triggers for the $11M in current convertible notes and the $2.8M loan payable, given the liquidity constraints.
• Revenue Transition: Assess the timeline for converting industrial AI Nose pilots into revenue-generating contracts to replace the lost revenue from pet supplements and healthcare pilots.
• Dilution Risk: Monitor the usage of the ATM facility and the potential conversion of outstanding warrants (381,953 shares) and convertible notes into equity, which could significantly dilute existing shareholders.
• Related Party Transactions: Review the terms of the loan and convertible notes with ASE Test, Inc., a related party, to ensure terms are arm's length.